Ginsenoside Rb1 Inhibits the Proliferation of Lung Cancer Cells by Inducing the Mitochondrial-mediated Apoptosis Pathway. 2024

Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
College of Pharmacy, Changchun University of Chinese Medicine, Changchun, 130117, China.

BACKGROUND Lung cancer is one of the more common malignant tumors posing a great threat to human life, and it is very urgent to find safe and effective therapeutic drugs. The antitumor effect of ginsenosides has been reported to be a treatment with a strong effect and a high safety profile. OBJECTIVE This paper aimed to investigate the inhibitory effect of ginsenoside Rb1 on 95D and NCI-H460 lung cancer cells and its pathway to promote apoptosis. METHODS We performed the CCK-8 assay, fluorescence staining assay, flow cytometry, scratch healing assay, and Transwell assay to detect the effects of different concentrations of ginsenoside Rb1 on the antitumor activity of 95D and NCI-H460 cells and Western Blot detected the mechanism of antitumor effect. RESULTS Ginsenoside Rb1 treatment significantly increased the inhibition and apoptosis rates of 95D and NCIH460 cells and inhibited the cell cycle transition from S phase to G2/M. Rb1 induces apoptosis by altering the levels of P53, Bax, Cyto-c, Caspase-8, Caspase-3, Cleaved Caspase-3, Bcl-2, MMP-2, and MMP-9 proteins and activating the external apoptotic pathway. CONCLUSIONS Ginsenoside Rb1 inhibits proliferation and migration and induces apoptosis of 95D and NCI-H460 lung cancer cells by regulating the mitochondrial apoptotic pathway to achieve antitumor activity.

UI MeSH Term Description Entries

Related Publications

Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
November 2008, The Journal of pharmacy and pharmacology,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
December 2017, Biological & pharmaceutical bulletin,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
December 2019, Artificial cells, nanomedicine, and biotechnology,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
August 2015, Molecular medicine reports,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
March 1998, Methods and findings in experimental and clinical pharmacology,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
September 2015, Oncology letters,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
March 2010, Natural product research,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
June 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
May 2014, Molecular biology reports,
Lin Feng, and Xinze Liu, and Kaijing Sun, and Ying Sun, and Wei Wu, and Changbao Chen, and Xin Jin, and Xilin Wan
June 2018, Oncology reports,
Copied contents to your clipboard!